Episode Details
Back to Episodes
Vera’s Kidney Data Strengthen Full-Approval Case & Curium Challenges Novartis’ Lutathera
Description
Vera reports a 76% reduction in composite kidney-disease progression risk and near-stable two-year kidney function for TRUTAKNA (atacicept-vymj) in sponsor topline data, addressing the clinical-benefit question behind its accelerated approval in IgA nephropathy. Curium's BEXLUTRY (lutetium Lu 177 dotatate) brings an adult neuroendocrine-tumor competitor to Lutathera, with delivery and access questions still open. GSK buys a preclinical myeloma development bet, while Lilly backs nervous-system genetic-medicine delivery. We also examine Connect's mixed asthma data, portfolio changes, longer-term lung-cancer evidence and the FDA's trial-startup pilot.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.